RecruitingNCT06600659
A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase
A Pilot Study to Establish Incidence and Characteristics of Patients at Risk for Symptomatic Hyperammonemia Secondary to Recombinant Erwinia Asparaginase
Sponsor
Mayo Clinic
Enrollment
10 participants
Start Date
Nov 2, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.
Eligibility
Min Age: 1 Year
Inclusion Criteria2
- Followed by pediatric hematology/oncology
- Receiving recombinant Erwinia asparaginase for treatment of malignancy
Exclusion Criteria2
- Patients \< 1 year of age
- Patients who have previously received recombinant Erwinia asparaginase within the past two weeks
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06600659
Related Trials
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
NCT0569149123 locations
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962187 locations
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
NCT060134231 location
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
NCT062716161 location
Acupressure for the Reduction of Anxiety in Patients Receiving Cancer-Directed Therapy
NCT067230411 location